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Abstract 
The availability of commercial 68Ge/68Ga cyclotron-independent 68Ga3+ generators is 
making Positron Emission Tomography (PET) accessible to most hospitals, which is 
generating a surge of interest in the design and synthesis of bi-functional chelators for 
Ga3+. In this work we introduce the NO2A-N-(-amino)propionic acid family of 
chelators based on the triazacyclononane scaffold. Complexation of the parent NO2A-
N-(-amino)propionic acid chelator and of a low molecular weight (model) amide 
conjugate with Ga3+ was studied by 1H and 71Ga NMR. The Ga3+ chelate of the amide 
conjugate shows pH-independent N3O3 coordination in the pH range 3-10 involving the 
carboxylate group of the pendant propionate arm in a 6 member chelate. For the 
Ga[NO2A-N-(-amino)propionate] chelate, a reversible pH-triggered switch from Ga3+ 
coordination  to the carboxylate group to coordination to the amine group of the 
propionate arm, was observed upon pH increase/decrease in the pH range 4-6. This 
phenomenon can conceivably constitute the basis of a physiological pH sensor.  Both 
complexes are stable in the physiological range. The [67Ga][NO2A-N-(-
benzoylamido)propionate] chelate was found to be stable in human serum. 
Biodistribution studies of the 67Ga3+-labeled pyrene butyric acid conjugate NO2A-N-(-
pyrenebutanamido)propionic acid revealed that, despite its high lipophilicity and 
concentration-dependent aggregation properties, the chelate follows mainly renal 
elimination with very low liver/spleen accumulation and no activity deposition in bones 
after 24 hours. Facile synthesis of amide conjugates of the NO2A-N-(-
amino)propionic acid chelator, serum stability of the Ga3+chelates and fast renal 
elimination warrant further evaluation of this novel class of chelators for PET 
applications.  
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Introduction 
Endowing thermodynamically stable and kinetically inert metal chelates with 
conjugability is the subject of intense research given the plethora of properties offered 
by metal ions for imaging and therapy. Non-functionalised metal chelates exhibit high 
hydrophilicity, distribution into the interstitial compartment, fast renal clearance and 
featureless biodistribution profiles. Delivering metal chelates to injury sites, for imaging 
and/or therapeutic purposes, allows reducing the dose and background signals and 
minimizes potential harmful side effects on non target organs- especially critical with 
complexes of metal-radioisotopes.  
Positron Emission Tomography (PET) is well established in clinical diagnostic 
for functional imaging thanks to its remarkably high detection sensitivity, relatively high 
spatial resolution and potential to quantify tracer uptake within lesions. 18F, 11C, 13N are 
the most used radionuclides for PET imaging due to their positron emission properties 
and short lifetimes. These radionuclides are covalently incorporated into biomolecules 
(sugars, amino acids, etc) through chemical synthesis, starting from simple precursor 
molecules/ions generated in dedicated cyclotron units.1 Molecules labeled with 11C and 
13N are indistinguishable from the natural abundance stable isotope unlabelled 
molecules undergoing the same metabolic pathways. C-2 18F labeled glucose (2-Deoxy-
2-[18F]fluoroglucose- FDG) is the most widely used tracer in clinical PET imaging. 
Following uptake by the glucose transporters and phosphorylation, FDG is trapped 
inside cells as FDG-6-P, allowing visualization in vivo of glucose avid cells and tissues. 
18F decay allows the resulting 2-[18OH]glucose to follow the normal glycolytic 
pathway.2,3 18F, and especially 11C and 13N-labelled PET tracers, half-lives of 109.8, 
20.3, and 9.96 minutes, respectively, need to be produced in loco in dedicated cyclotron 
units, using fast, high yielding synthetic procedures coupled to expeditious purification 
schemes  (operated remotely) to avoid substantial loss of activity.1,2,3  
Many metal ion radionuclides (eg. 68Ga3+, 64Cu2+) also display positron emission 
properties suitable for PET imaging.4 Amongst these, 68Ga3+, 89% positron branching 
accompanied by low photon emission (1077 keV, 3.22 %) and half live of 67.6 minutes, 
is suitable for labelling molecules with fast blood clearance.5,6 The commercial 
availability of 68Ge/68Ga cyclotron-independent 68Ga3+ generators is making PET 
imaging available to most hospitals.7 Labeling (bio)molecules with metal ion 
radionuclides requires efficient pathways to attach covalently bi-functional chelators 
(post-conjugation labeling), or functionalized chelates (pre-conjugation labeling) to 
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biomolecules.4,5,6,7 High thermodynamic stability and kinetic inertness of the metal 
complexes is absolutely mandatory for safe and efficient PET imaging.8,9,10 Transferrin, 
the iron transport protein, is the main competitor for Ga3+ in serum given the similar 
ionic radius and coordination properties of Fe3+ and Ga3+.11 In addition to stability, fast 
complexation, ideally at room temperature, and efficient purification procedures of 
labeled conjugates, have to be taken into account in the design of new chelators for Ga3+ 
for use as PET tracers.12 Moreover, complex formation with Ga3+, obtained as 68GaCl3 
by elution of 68Ge/68Ga generators with diluted hydrochloric acid, must be carried out at 
pH values below 4 (usually in acetate or HEPES buffer) to avoid precipitation of Ga3+ 
as Ga(OH)3.
13,14 
The coordination chemistry of Ga3+ is dominated by its hard character, preferring hard, 
charged base donors such as carboxylates, phosphonates and phosphinates in an 
octahedral geometry,10 although it has also been shown to have good affinity for 
thiolates, such as TACN-TM (TACN-TM = 1,4,7-triazacyclononane-N,N´,N´´-
tris(mercaptoethyl)).10,15 Poly(aminocarboxylates) and poly(aminophospho 
nates/phosphinates) are the most efficacious chelators for Ga3+. Macrocyclic, DOTA-
type (DOTA= 1,4,7,10-tetrazacyclododecane-1,4,7,10-tetraacetic acid) and NOTA-type 
(NOTA= 1,4,7-triazacyclononane-1,4,7-triacetic acid) chelators form Ga3+ complexes 
displaying exceptional thermodynamic stability and kinetic inertness.12,16,17,18 Ga3+ 
complexes of linear, DTPA19 (DTPA= diethylenetriamine pentacetic acid) and EDTA-
type20 (EDTA= ethylenediaminetetraacetic acid) chelators were found to be kinetically 
too unstable for in vivo use, despite the high thermodynamic stability of its Ga(EDTA)- 
and Ga(DTPA)2- complexes.21,22 DOTA-monoamide (octadentate) chelators, developed 
originally as Gd3+ complexing agents for use as Contrast Agents (CA) for Magnetic 
Resonance Imaging (MRI), despite forming Ga3+ complexes exhibiting lower 
thermodynamic stability and higher kinetic lability than the parent Ga(DOTA)- 
complex, are still kinetically inert enough for in vivo PET.12 The peptide conjugate 
[68Ga](DOTATOC) (DOTATOC = DOTA, Tyr3-octreotide) is worldwide used in 
hospitals for diagnostic of neuroendocrine tumors expressing somatostatin receptors.23,24 
The macrocycle cavity of DOTA-type chelators, optimal for Ln3+ ions, is too big for 
Ga3+ complexation, originating distorted octahedral (N4O2) complexes.
10,12,23,24  Good 
matching of the macrocycle cavity of NOTA with the ionic radius of Ga3+ results in 
Ga(NOTA) complexes exhibiting exceptional thermodynamic stability and kinetic 
inertness.16,17 Moreover, NOTA-type chelators display faster Ga3+ chelation kinetics at 
5 
 
lower temperatures than DOTA-type chelators.25 NOTA-monoamide conjugates, 
although amenable through facile synthetic routes, are likely to result in complexes 
exhibiting lower thermodynamic stability and higher kinetic lability than their parent 
Ga(NOTA) complex, compromising their potential for biological applications.26 
Replacing an acetate arm on the NOTA scaffold by an acetate group -substituted with 
a reactive group endows the NOTA scaffold with conjugability whilst preserving its 
N3O3 denticity mandatory for stable coordination with Ga
3+. The aspartate and 
glutamate derivatives of NOTA,  NODASA (NODASA = 1,4,7-triazacyclononane-N-
succinic-N´,N´´-diacetic acid)27 and NODAGA (NODAGA = 1,4,7-triazacyclononane-
N-glutaric-N´,N´´-diacetic acid)),28 respectively, are the gold standards for the synthesis 
of targeted Ga3+ tracers for PET. More recently, the TRAP (TRAP = 1,4,7-
triazacyclononane-1,4,7-tris(methylenephosphinic acid)) family of chelators, generated 
by replacement of the pendant carboxylates by phosphinate groups on the 
triazacyclononane macrocycle scaffold, revealed excellent chelating properties for Ga3+ 
allied to conjugability.29,30,31 Tris-NODASA/NODAGA32 and tris-TRAP29 derivatives 
allow facile preparation of multivalent conjugates with biomolecules such as peptides, 
exhibiting enhanced avidity (affinity and/or specificity) for cellular receptors. Pendant 
reactive groups on the ethylenediamine bridges of the NOTA scaffold allow also 
bioconjugation whilst retaining the high thermodynamic stability and kinetic inertness 
of the Ga(NOTA) complex, although at the expense of difficult and lengthy synthetic 
pathways.33 
In our efforts to obtain thermodynamically stable and kinetically inert conjugates of 
metal chelates as potential medical imaging agents, we have reported recently efficient 
methodologies for the synthesis of the DO3A-N-(-amino)propionate chelator34 and for 
the preparation of amide conjugates.35,36,37 The Gd[DO3A-N-(-amino)propionate] 
chelate and its amide conjugates combine high thermodynamic stability and kinetic 
inertness with (fast) water exchange properties ideal for attaining high relaxivities at 
(intermediate/high) fields relevant for Magnetic Resonance Imaging.34,35,36,37 In this 
work we extend the synthetic methodologies developed for DO3A-N-(-
amino)propionate chelators to the triazacyclononane scaffold. This includes the NO2A-
N-(-amino)propionic acid (L1) chelator and the two amide derivatives NO2A-N-(-
benzoylamido)propionic acid (L2) and NO2A-N-(-pyrenebutanamido)propionic acid 
(L3) (see Scheme 1). The complexation of the new chelators with Ga3+ was studied by 
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multinuclear NMR (1H, 71Ga). The luminescence properties of the GaL3 complex were 
also analysed in order to evaluate its potential as a bimodal PET/optical imaging agent. 
Serum stability and biodistribution studies were also performed to evaluate the potential 
of the new chelators as 68Ga3+-labeled PET tracers.   
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Results and Discussion 
Synthesis and Characterization 
In this work we aimed at extending the synthetic methodologies developed for DO3A-
N-(-amino)propionate chelators34,35,36,37  to the triazacyclononane scaffold,  to explore 
the coordination properties of  NO2A-N-(-amino)propionic acid chelators for Ga3+ as 
potential tracers for PET imaging (Scheme 1). 
 
 
Scheme 1. Synthetic pathway for the metal chelators NO2A-N-(α-amino)propionic acid (L1), 
NO2A-N-(α-benzoylamido)propionic acid (L2) and NO2A-N-(-pyrenebutanamido)propionic 
acid (L3): a) K2CO3/MeCN; b) tert-Butyl bromoacetate, K2CO3/MeCN; c) i. Hydrochloric 
acid/EtOH, ii. Dowex-1X2-OH-, elution with diluted hydrochloric acid; d) GaCl3. xH2O; e) i. 
TFA/CH2Cl2; ii. Ethyl bromoacetate, K2CO3/MeCN; f) Dowex-1X2-OH-, elution with diluted 
hydrochloric acid.   
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Michael addition of the Boc2--AlaOMe (2)34 and Boc(Amide)--AlaOMe 
blocks 336 and 437 to triazacyclononane (1) proceeds smoothly in acetonitrile at room 
temperature using K2CO3 as base in 3-4 hours as reported before for the cyclen 
analogue. An excess of triazacyclononane, 1.5 molar equivalents, affords the 
monoalkylated nonanes as main reaction products. Small amounts of bis- and tris-
alkylated derivatives are easily removed by flash chromatography. Further N-alkylation 
of nonane 5 with tert-butyl bromoacetate, followed by sequential deprotection with 
hydrochloric acid (4 M) and Dowex1X2-OH- resin and elution with diluted hydrochloric 
acid afforded the NO2A-N-(-amino)propionic acid chelator (L1) as hydrochloride in 
(non-optimised) 36% overall yield. Alkylation of monoalkylated cyclen 5 with ethyl 
bromoacetate offers the opportunity to deprotect selectively the amine group for further 
conjugation.35 This (direct) conjugation pathway was not pursued in this work. Instead, 
we have explored the indirect pathway for preparing amide conjugates of the NO2A-N-
(-amido)propionic acid chelator.36 The NO2A-N-(-benzoylamido)propionic acid 
chelator (L2) is likely to result in soluble non-associating chelates; the pyrenyl 
conjugate NO2A-N-(-pyrenebutanamido)propionic acid chelator (L3) was designed as 
a self-assembling, fluorescent chelator potentially useful for bimodal PET/fluorescence 
imaging.37 Michael addition of Boc(dehydroamide)--AlaOMe blocks introduces 
directly the amide (targeting/kinetic modulator) group into the triaza scaffold.  
Removing the Boc group at the monoalkylated stage averts retro-elimination during the 
second alkylation step. One step deprotection of the ester protected prochelators with 
Dowex1X2-OH- affords the fully deprotected chelators as hydrochlorides after resin 
elution with aqueous hydrochloric acid.  
Many other amide conjugates are accessible using the expeditious 
methodologies described in this work.  
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1H and 71Ga NMR studies 
Given the current interest on 68Ga PET, unleashed by the commercial availability of 
cyclotron-independent 68Ga generators,4,5,6,7 we carried out a multinuclear NMR study 
(1H and 71Ga) of the GaL1 and GaL2 chelates to ascertain the coordination properties of 
the novel chelators and their potential for PET imaging applications. 
71Ga (38.89 %) is a quadrupolar nucleus (I = 3/2) exhibiting a relatively high receptivity 
and a wide range of chemical shifts.38 The quadrupolar nature of its relaxation 
mechanism leads to NMR signals whose linewidth is sensitive to the symmetry of the 
coordination environment. Spherical, octahedral, cubic and tetrahedral symmetries 
should, in principle, originate sharp 71Ga NMR signals. This is the case for NOTA-type 
triazamacrocyclic complexes, whose predominant coordination geometry is distorted 
octahedral, as opposed to DOTA-type tetraazamacrocyclic complexes like Ga(DOTA)- 
and its monoamide derivatives, whose low coordination symmetry makes their 71Ga 
NMR signals to broad to be detected.12 The chemical shift is characteristic of the 
coordination geometry of the metal ion.39,40  
The pH dependence of the 1H (Figure 3) and 71Ga NMR spectra (Figure 1) for the GaL1 
and GaL2 complexes was studied in D2O to probe the coordination environment of the 
Ga3+ metal ion.  
A)              B) 
  
 
Figure 1. pH dependence of the 71Ga NMR spectra for: (A) the GaL1 and (B) GaL2 complexes 
(20 mM in D2O, 25 ºC).  
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Table 1 summarizes the 71Ga NMR chemical shifts and linewidths for the species 
observed in solution for the GaL1 and GaL2 complexes studied in this work, compared 
with other triazamacrocyclic complexes reported in the literature (Figure 2). 
 
Table 1. 71Ga NMR chemical shifts and linewidths for the GaL1 and GaL2 
complexes studied in this work, compared with other triazamacrocyclic 
complexes reported in the literature.40 
Complex  (ppm) 1/2 (Hz) Coordination 
GaL1
a        
 
+ 141 
+ 186 
900 
550 
N3O3 
N4O2 
GaL2
a + 140 900 N3O3 
Ga(NOTA)b + 171 235 N3O3 
Ga(NO2A-N-Methylacetamide)c  
 
Ga(NO2A-N-Benzylacetamide)c 
+ 171 
+ 175 
+ 170 
+ 174 
283 
9085 
279 
4818 
N3O3 
N4O2 
N3O3 
N4O2 
Ga(NOTP)d + 110 434 N3O3 
Ga(NOTMP)e + 136 215 N3O3 
 
Ga(TRAP-H)f 
+ 132 
+ 134 
+ 138 
+ 141 
154 
200 
186 
162 
N3O3 
N3O3 
N3O3 
N3O3 
aThis work; bref. 17,41; cref. 42; dref. 43; eref. 44; fref. 30   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Struture of triazacyclononane ligands compared in Table 1 and discussed in the 
manuscript: NOTP (1,4,7-triazacyclononane-N,N´,N´´-tris(methylenephosphonic) acid); 
NOTMP (1,4,7-triazacyclononane-N,N´,N´´-tris(methylene(metylphosphinate))); TRAP-H 
(1,4,7-triazacyclononane-1,4,7-tris(methylenephosphinic acid). 
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The number and population of the species present over the pH range 3-11, as 
well as their chemical shifts and linewidths are quite different for the GaL1 and GaL2 
complexes. 
The GaL2 complex displays only one 71Ga NMR signal in the pH range 3-9: a 
singlet at = 140 ppm with a relatively large linewidth, 1/2 = 900 Hz. Above pH 9.0, 
hydroxide catalyzed demetallation leads to the formation of the [Ga(OH)4]
- species 
characterized by a sharp signal at = 224 ppm.40 In contrast, the 71Ga NMR spectrum of 
the GaL1 chelate is pH dependent. At pH 3.0 there is only one signal with a chemical 
shift (141 ppm) and width (900 Hz) identical to that displayed by the GaL2 complex. A 
new sharper (1/2 = 550 Hz) signal at = 186 ppm becomes apparent at pH 4.1. The 
intensity of this signal increases, at the expense of the signal at = 141 ppm, when the 
pH increases, eventually becoming the only signal in the pH range 6-10. At pH 11, the 
[Ga(OH)4]
- species is also present. This process is fully reversible, reproducing the same 
features upon pH decrease. These results strongly suggest that for the amide complex 
GaL2, the coordination polyhedron is likely to be represented by a distorted octahedron 
involving the carboxylate group of the propionate arm to form a six member chelate 
(coordination polyhedron N3O3). Although coordination through the amide nitrogen, 
forming a five member chelate, is also possible, the preference of the hard Ga3+ ion for 
the carboxylate group is likely to compensate for the energy cost of forming a six 
member chelate.42 The GaL1 chelate seems to undergo the same chelation scheme 
(N3O3) as the amide complex at low pH, presumably due to the unavailability of the 
protonated amine group for binding. At higher pH (6-11) the formation of a five 
member chelate with the deprotonated amine group (coordination polyhedron N4O2) 
seems to be more favorable than the formation of a six member chelate with the harder 
carboxylate group. The N4O2 chelation mode for the GaL1 chelate (all five member 
chelates) is likely to generate a coordination polyhedron of higher symmetry, similar to 
Ga(NOTA), than the N3O3 geometry involving a six member chelate- thus, the sharper 
71Ga NMR signal and higher chemical shift of the N4O2 isomer of GaL1 at pH 6-11. For 
the GaL3 complex at 20 mM concentration the 71Ga NMR spectrum becomes too broad 
to be measured reflecting provably the micellar state of the complex.45 Both GaL1 and 
GaL2 complexes are stable in the physiological pH range undergoing hydroxide 
catalyzed demetallation above pH 10 and 9, respectively.  
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This is apparent in the 71Ga NMR spectra by the disappearance of the signals 
assigned to the complexes and by the appearance of the sharp signal at = 224 ppm, 
assigned to the [Ga(OH)4]
- ion.  All known Ga3+ complexes undergo hydroxide 
catalyzed demetallation in the alkaline pH region.40 In this respect, the GaL1 complex 
seems to be more stable than the amide conjugate GaL2 chelate, requiring a higher pH 
for complete demetallation. This can be ascribed to the preference for the N4O2 
coordination for the GaL1 complex at high pH, compared to the N3O3 coordination of 
GaL2. A similar isomerization process involving coordination of the Ga3+ ion to the 
nitrogen or oxygen atom of the amide linkage (five member chelates), has been 
observed for the Ga(NO2A-N-Benzylacetamide) and Ga(NO2A-N-Methylacetamide) 
complexes (Figure 2 and Table 1), both in the solid state and in aqueous solution. At low 
pH the N3O3 coordination predominates over N4O2 coordination.
42 As can be seen in 
Table 1, the two isomers of the Ga(NO2A-N-Benzylacetamide) and Ga(NO2A-N-
Methylacetamide), involving in both cases five member chelates, show much smaller 
shift differences and are much broader than the isomers found in the present study for 
GaL1. The phosphonate complex Ga(NOTP)43 and some phosphinate complexes, like 
Ga(NOTMP)44 lead to the presence of only one species in solution. In all the NOTA-
type complexes with N3O3 coordination the Ga
3+ ion is placed between twisted trigonal 
O3 and N3 planes, an arrangement which leads to chiral complexes. This is caused by 
the combination of the conformation of the chelate rings in the macrocyclic moiety 
(/) with the helicity of the coordinated pendant arms (/), which leads to two 
diastereoisomeric pairs /and/In the NOTA derivatives bearing 
three phosphinate pendant arms, those chiralities are combined with the R/S chirality of 
the phosphorus atom upon metal coordination, leading to four possible diastereomeric 
pairs, RRR/SSSRRS/SSRRSS/SRR 
andSSS/RRRIn the Ga3+ phosphinate complexes with alkyl 
substituents (CH3 in Ga(NOTMP)
44 or CH2OH in Ga(TRAP-OH)
30, only the 
RRR/ SSS diastereoisomer is observed in solution, leading to a single 
71Ga signal, while for more electron-withdrawing substituents, like H in Ga(TRAP-H)30, 
the full mixture of possible isomers is observed in solution as a set of four narrow 
resonances with very small shift differences (Table 1).  
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The 1D 1H and 2D COSY and NOESY spectra of the GaL1 complex solutions 
were also obtained at 25 ºC in the pH 3.0-9.0 range, and at pH 3.0-5.5 for GaL2. The 
proton resonance signals from the macrocyclic backbones were only tentatively 
assigned due to superimposed multiplet signals in the 3.7-2.8 ppm range (Figures S1 
and S2). The NCH2CO2H acetate arm protons give a multiplet at 3.85 ppm, while the 
phenyl group of GaL2 originates three multiplets at 7.70, 7.45 and 7.40 ppm with a 
2:2:1 intensity ratio, corresponding to the ortho, para and meta CH protons. The most 
informative resonances correspond to the NCH2CH protons of the substituted 
propionate arm of the complexes, in the form of a characteristic ABX pattern, with the 
CH proton resonances outside the envelope of the other protons (Figures S1 and S2). 
The AB patterns of the CH2 signal coupled to the CH group (NCH2CH) could be traced 
in the COSY spectra of both complexes (Figures S1 and S2). In the case of GaL2 the 
CH multiplet has a single component at 5.05 ppm (Figure 3), in accordance with the 
single 71Ga resonance at +140 ppm, corresponding to N3O3 coordination (Figure 1). In 
the case of GaL1 the CH proton signals are pH-dependent, in parallel with what was 
observed for the 71Ga NMR spectra (Figure 3). While at pH 3.3, it consists of a single 
multiplet (doublet of triplets) at 4.47 ppm (labeled I), corresponding to the single 71Ga 
resonance at 141 ppm (N3O3 coordination isomer), at pH 4.1 there are two CH 
multiplets at 4.50 (I) and 4.38 ppm (II), corresponding to the 71Ga signals at 141 and 
186 ppm, assigned to the N3O3 and N4O2 isomers, respectively. The relative intensity of 
the N4O2 signals (4.38 ppm and 186 ppm) increases with pH in  relation to the N3O3 
signals (4.50 and 141 ppm) and at pH 6.1 only the 4.38 ppm signal is present. The 
corresponding CH2 multiplets are observed between 3.60 and 3.20 ppm (Figures S1 and 
S2). Therefore, the proton NMR spectra confirm the isomer information provided by the 
71Ga NMR spectra. 
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Figure 3. pH dependence of the proton  NMR resonances of the CH protons of the propionate 
side arm of: (A) GaL1  and (B) GaL2 complexes (400 MHz, 20 mM in D2O, 25 ºC).  
 
Fluorescence studies 
The GaL3 complex was designed to have properties compatible with a bimodal 
PET/Fluorescence imaging agent. The lipophilic pyrene moiety was selected due to its 
special aggregation-sensitive fluorescence properties.37,46 The absorption (Figure S3) 
and the fluorescence emission properties (Figure S4) of the free ligand L3 and of the 
GaL3 complex (Figure 4) were studied in non-deoxygenated water (pH 7.0) by UV-Vis 
and steady-state fluorescence spectroscopy (Table 2). 
 
Table 2. Quantum yields (F) for the ligand L3 and GaL3 complex (ex 345 nm) 
in non-deoxygenated water. 
 
F 
a,b 
L3 GaL3 
0.20 0.30 
    
aRelative to anthracene in ethanol ( = 0.27) 
 bLigand and complex at 1.0x10-6 M concentration, non-deoxygenated solutions 
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The absorption spectra of L3 and GaL3 (1x10-5 M, pH 7.0) exhibit bands in the 
wavelength range 300-350 nm characteristic of pyrene intraligand * transitions 
(Figure S3).47  The steady state fluorescence spectra of L3 (Figure S4) and GaL3 (Figure 
4) at low micromolar concentrations (1x10-6 M, ex= 345 nm) display the typical 
vibronically structured band, attributed to the pyrene monomer (1* transitions).37,48 
The fluorescence quantum yields for L3 and for the pyrene-centred emission in GaL3 are 
of the same order of magnitude as those reported for other pyrene conjugates.37,47,48 
Complex formation with diamagnetic Ga3+ enhances slightly the fluorescence quantum 
yield of L3. The concentration dependence of the steady state fluorescence properties of 
L3 (Figure S4) and GaL3 (Figure 4) indicate that both ligand and complex undergo self-
assembly, presumably into micelle-type structures, in aqueous solution.  
 
 
Figure 4. Normalized fluorescence spectra for GaL3 in non-deoxygenated water over the 
concentration range 5x10-7-5x10-3 mol.dm-3 (exc= 345 nm).  
 
Increasing the concentration of L3 and GaL3 triggers a gradual switch from the 
characteristic structured pyrene monomer spectrum to the broad featureless typical  
excimer (excited dimer) spectrum, indicating self-assemby in solution, presumably in 
the form of micelle-type structures.37 Attempts to calculate the critical micelle 
concentration (cmc) for L3 and GaL3 by fitting the concentration dependence of the 
ratio of fluorescence emission intensity for the excimer (490 nm) and for the monomer 
(377 nm) (IE/IM) to a sigmoidal curve model revealed unsuccessfull.
37,49,50  Nonetheless, 
the concentration-dependent aggregation-sensitive nature of the fluorescence emission 
is clearly observable.  
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Above the cmc aggregates and monomers (at a concentration equal to the cmc 
value) are present in solution. Increasing ligand or chelate concentration above the cmc, 
leads to an increase of the number of micelles enhancing excimer emission. 
 
In vitro stability and biodistribution studies 
The kinetic stability of the [67Ga]L2 chelate towards in vivo transchelation was assessed 
by incubating the 67Ga3+-labeled chelate with fresh human serum, followed by 
precipitation of the protein fraction and measurement of the activity in the pellet and in 
the soluble fraction (Figure 5). 
 
Figure 5. Percentage of activity in the protein and in the soluble fraction at different incubation 
times of [67Ga]L2 with human serum. 
 
The percentage of total activity in the protein pellet reached immediately a value 
of 10% after incubating the complex with serum. This value remained constant over 1 
hour incubation, revealing early association of the complex with blood proteins, 
presumably involving the lipophilic benzoyl moiety (Log Pcalculated(GaL2)= 0.69, see SI).  
Radio-TLC analysis of the soluble fraction after 1 hour incubation revealed that the 
complex remains intact. 
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Biodistribution profiles were obtained for the [67Ga]L3 labelled complex at 1 and 
24 hour post-injection in Wistar rats (Figure 6, Table S1).  
 
 
Figure 6. Biodistribution profiles, stated as % injected activity per gram of organ or tissue, for 
the [67Ga]L3 complex at 1 and 24 hours post-injection. Results are the average of 4 animals. 
 
At 1 hour post-injection the activity is manly located in the kidneys, liver and 
blood and to a lesser extent in the lungs and intestine. The high kidney uptake, 
comparing to liver, indicates that the main elimination pathway is renal. The relatively 
high activity in the blood at 1 hour post injection suggests association of the complex 
with plasma proteins, presumably albumin or lipoproteins, presumably through the 
lipophylic pyrene moiety (Log Pcalculated.(GaL3)= 3.31, see SI).
37 The very low spleen 
and lung uptake suggests that in the blood the complex is not aggregated. A motivating 
factor for performing the biodistribution study was to ascertain potential brain uptake of 
GaL3. Biodistribution studies of the analogous [153Sm][DO3A-N-(-
pyrenebutanamido)propionate] complex suggested a low, although not negligible, 
activity uptake at the brain-cerebellun at 1 hour pi.37 The higher lipophilicity of GaL3 
(overall neutral complex) comparing to its DOTA analogue Sm[DO3A-N-(-
pyrenebutanamido)propionate] complex (overall charge -1) could plausibly result in 
higher brain uptake. The current study excludes uptake of [67Ga]L3 by the brain. Most 
importantly, no significant activity remains in the liver and spleen and there is no 
activity deposition in the bones after 24 hours, indicating that complex demetalllation is 
not occurring in vivo.   
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Conclusions 
 
In this work we extend the synthetic pathways, reported previously for the 
DO3A-N-(-amino)propionate family of chelators, to the triazacyclononane scaffold. A 
reversible pH-triggered switch from Ga3+ coordination to the carboxylate group of the 
substituted propionate arm (at pH values bellow 4.0) to amine coordination (at pH 
values above 6.0), was uncovered by 1H and 71Ga NMR studies of the Ga[NO2A-N-(-
amino)propionate] complex. The Ga3+ chelate of the benzoylamide conjugate displays 
pH-independent Ga3+ complexation to the carboxylate of the amide-substituted 
propionate arm in the pH range 3-11. Both complexes are stable in the physiological pH 
range. Moreover, the [67Ga][NO2A-N-(-benzoylamido)propionate] chelate is also 
stable in human serum. The pyrenebutyric acid conjugate, Ga[NO2A-N-(-
pyrenebutanamido)propionate] chelate,  was designed as a potential bimodal 
PET/Fluorescence imaging agent with aggregation-sensitive fluorescence properties. 
The facile synthesis of conjugates of the NO2A-N-(-amino)propionic acid chelator, 
together with the serum stability of their Ga3+chelates and fast renal elimination of the 
lipophilic pyrene conjugate, without any liver/spleen retention and activity deposition in 
the bones, warrant further evaluation of this novel class of chelators as potential tracers 
for PET. The reversible pH-triggered coordination switch demonstrated for the 
Ga[NO2A-N-(-amino)propionate] complex can conceivably be translated into a 
method for pH measurement in vivo by 71Ga NMR.    
 
Experimental 
Materials and methods 
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Analytical grade solvents were used and not further purified unless specified. Reactions 
were monitored by TLC on Kieselgel60 F254 (Merck) on aluminum support, with 
detection by examination under UV light (254 nm, 365 nm), by adsorption of iodine 
vapor and by spraying with ninhydrin. Flash chromatography was performed on 
Kieselgel60 (Merck, mesh 230-400). Ion exchange chromatography was performed on 
Dowex1X2-OH- resin (Sigma Aldrich). The resin was purchased as the Cl- form and 
converted to the OH- form by the standard procedure.  
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The relevant fractions from chromatography were pooled and concentrated under 
reduced pressure, T < 40 oC. 1H and 13C NMR spectra (assigned by 2D DQF-COSY and 
HMQC techniques) were run on a Varian Unity Plus 300 and a Bruker Avance-3 400 
Plus NMR spectrometers, operating at 299.938 MHz and 75.428 MHz, and 400.13 MHz 
and 100.61 MHz, for 1H and 13C, respectively. 1H 1D and 2D DQF-COSY and NOESY 
spectra were also run on a Varian VNMRS 600 at 599.72 MHz. Chemical shifts (δ) are 
given in ppm relative to the CDCl3 solvent (
1H, δ 7.27; 13C 77.36) as internal standard. 
For 1H and 13C NMR spectra recorded in D2O, chemical shifts (δ) are given in ppm, 
respectively, relative to TSP as internal reference (1H, δ 0.0) and tert-butanol as external 
reference (13C, CH3 δ 30.29). 71Ga NMR spectra were recorded at 122.026 MHz on a 
Bruker Avance-3 400 Plus spectrometer, using the signal of [Ga(H2O)6]
3+ present in a 
0.1 M Ga(NO3)3 solution in D2O,  at 0 ppm as external reference. pH measurements 
were performed on a pH meter Crison micro TT 2050 with an electrode Mettler Toledo 
InLab 422. For D2O solutions, the isotopic correction pD = pH + 0.4
 was done.51 Mass 
spectrometry was performed at CACTI- Vigo, Spain.  
 
Synthetic procedures  
Preparation of monoalkylated nonanes 5, 6 and 7. 
 
Synthesis of bis(tert-butoxycarbonyl)amino-methoxycarbonylethyl-1,4,7-triaza 
cyclononane - Monoalkylated nonane (5): Boc2--Ala-OMe (2) (158 mg, 0.51 mmol) 
was added in one portion to a suspension containing 1,4,7-triazacyclononane (98 mg, 
0.76 mmol) and K2CO3 (279 mg, 2.0 mmol) in MeCN (20 mL). The suspension was 
vigorously stirred at room temperature for 2 hours. The suspended solid was removed 
by filtration and the solvent was evaporated under reduced pressure. The residue was 
purified by flash chromatography (100% CH2Cl2  CH2Cl2/EtOH/NH4OH/H2O 
(50:50:1:1)) to afford compound 5 (120 mg, 55 %). 1H NMR (300 MHz, CDCl3): = 
1.51 (s, 18 H, Boc), 2.58-2.80 (m, 12 H, N(CH2)2N), 3.65 (dd, J=14.1 and 8.4 Hz, 1 H, 
ABX), 3.70 (dd, J = 14.1 and 4.5 Hz, 1 H, ABX), 3.71 (s, 3 H, C(O)OMe), 5.01 (dd, J= 
8.4 and 4.5 Hz, 1 H, ABX).13C NMR (75.4 MHz, CDCl3): 28.02 (C(CH3)3), 46.45 
(CH2), 46.83 (CH2), 52.16 (C(O)OCH3), 53.16 (CH2), 56.52 (CH2), 56.67 (CH), 83.34 
(C(CH3)3), 152.28 (C(O), carbamate), 170.73 (C(O), ester). HRMS (ESI): m/z: cacd for 
C20H39N4O6, [M+H]
+: 431.2864, found: 431.2859. 
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Synthesis of N-tert-butoxycarbonylbenzamido-methoxycarbonylethyl-1,4,7-triaza 
cyclononane - Monoalkylated nonane (6): (benzyl)Boc-Δ-AlaOMe (3) (385 mg, 1.23 
mmol) was added in one portion to a suspension containing 1,4,7-triazacyclononane 
(242 mg, 1.87 mmol) and K2CO3 (691 mg, 4.5 mmol) in MeCN (70 mL). The 
suspension was vigorously stirred at room temperature for 3 hours. The suspended solid 
was removed by filtration and the solvent was evaporated under reduced pressure. The 
residue was purified by flash chromatography (100% CH2Cl2 
CH2Cl2/EtOH/NH4OH/H2O (70:30:1:1)) to afford monoalkylated nonane 6 as a viscous 
light yellow oil (364 mg, 59 %). 1H NMR (300 MHz, CDCl3): δ= 1.47 (s, 9 H, 
C(CH3)3), 2.50-2.90 (m, 12 H, N(CH2)2N), 3.01 (dd, J= 14.1 and 6.0 Hz, 1 H, ABX), 
3.49 (dd, J= 14.4 and 5.1 Hz, 1 H, ABX), 3.76 (s, 3 H, C(O)OMe), 5.25 (t, J= 6.0 and 
5.1 Hz, 1 H, ABX), 7.30-7.70 (5 H, m, Ar). 13C NMR (75.4 MHz, CDCl3): δ= 27.27 
(C(CH3)3), 44.77 (CH2), 45.83 (CH2), 46.70 (CH2), 51.27 (CH2), 52.51 (C(O)OCH3), 
55.61 (NCH2CH), 56.08 (CH), 83.88 (C(CH3)3), 127.87 (Ar), 127.96 (Ar), 131.27 (Ar), 
137.02 (Ar), 152.72 (C(O), carbamate), 170.57 (C(O), amide), 172.62 (C(O), ester). 
HRMS (ESI): m/z: cacd for C22H35N4O5, [M+H]
+: 435.2602, found: 435.2601. 
   
Synthesis of methoxycarbonyl-(2-(N-t-butoxycarbonyl-4-pyrenebutanamido))-
ethyl-4,7-bis-(ethoxycarbonylmethyl)-1,4,7-triazacyclononane - Monoalkylated 7: 
(Pyrenyl)Boc-Δ-AlaOMe (4) (1.01 g, 2.14 mmol) was added in one portion to a 
suspension containing 1,4,7-triazacyclononane (0.43 g, 3.33 mmol) and K2CO3 (1.76 g, 
12.7 mmol) in MeCN (40 mL). The suspension was vigorously stirred at room 
temperature for 5 hours. The suspended solid was removed by filtration and the solvent 
was evaporated under reduced pressure. The residue was purified by flash 
chromatography (100% CH2Cl2 CH2Cl2/EtOH/NH4OH/H2O (70:30:1:1)) to afford 
monoalkylated nonane 7 as a viscous light yellow oil (0.76 g, 59 %). 1H NMR (300 
MHz, CDCl3): δ = 1.42 (s, 9 H, C(CH3)3), 2.21 (m, 2 H, NHC(O)CH2CH2), 2.64 (m, 8 
H, 2xN(CH2)2N), 2.90 (m, 1 H, ABX), 3.12 (m, 6 H, N(CH2)2N and NHC(O)CH2), 
3.38-3.50  (m, 3 H, NHC(O)CH2CH2CH2 and ABX), 3.43 (m, 2 H, N(CH2)2N),  3.70 (s, 
3 H, C(O)OMe), 5.44 (t, J= 6.9 and 4.8 Hz, 1 H, ABX), 7.95-8.40 (9 H, m, Ar). 13C 
NMR (75.4 MHz, CDCl3): δ= 27.03 (CH2), 27.83 (C(CH3)3), 32.83 (CH2), 37.85 (CH2), 
45.71 (CH2), 46.20 (CH2), 46.45 (CH2), 52.11 (CH2), 52.20 (C(O)OCH3), 54.24 (CH), 
58.17 (NCH2CH), 84.34 (C(CH3)3), 12344 (Ar), 123,87 (Ar), 124.72 (Ar)), 125,02 (Ar), 
125.76 (Ar), 126.58 (Ar), 127.28 (Ar)), 127.47 (Ar), 128.66 (Ar), 129.85 (Ar), 130.82 
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(Ar), 130.92 (Ar), 131.33 (Ar), 151.86 (C(O), carbamate), 170.75 (C(O), ester). HRMS 
(ESI): m/z: cacd for C35H45N4O5, [M+H]
+, 601.3390 , found: 601.3407. 
 
Synthesis of tris-alkylated nonanes 8, 9 and 10 
Synthesis of bis(tert-butoxycarbonyl)amino-methoxycarbonylethyl-4,7-bis-(tert-
butoxycarbonyl methyl)-1,4,7-triazacyclononane - tris-alkylated nonane 8: tert-
Butyl bromoacetate (85 L, 0.57 mmol) was added in one aliquot to a suspension 
containing monoalkylated compound 5 (100 mg, 0.23 mmol) and K2CO3 (125 mg, 0.90 
mmol) in MeCN (20 mL). The suspension was vigorously stirred at room temperature 
for 3 hours. The suspended solid was removed by filtration and the solvent was 
evaporated under reduced pressure. The residue was purified by flash chromatography 
(100% CH2Cl2 CH2Cl2/EtOH (50:50)) to afford tris-alkylated compound 8 (69 mg, 45 
%). 1H NMR (300 MHz, CDCl3): = 1.44 (s, 18 H, C(CH3)3, Boc), 1.65 (s, 18 H, 
C(CH3)3, ester), 2.75-3.78 (m(br) 12 H, N(CH2)2N), 3.03 (t, J= 4.2 Hz, 1 H, ABX), 3.20 
(t, J= 4.2 Hz, 1 H, ABX), 3.73 (s, 4 H, NCH2C(O)), 3.78 (s, 3 H, C(O)OMe), 5.01 (t, J= 
4.2 Hz 1 H, ABX).13C NMR (75.4 MHz, CDCl3): 28.02 (C(CH3)3, Boc and 
tBu ester), 
44.53 (3 C, NCHCH2, CH2), 50.80 (2 C, CH2), 53.16 (2 C, CH2), 52.33 (3 C, OCH3, 2 x 
CH2), 56.52 (CH), 81.00 (2 C, C(CH3)3), 83.50 (2 C, C(CH3)3), 150.59 (1 C, C(O)), 
151.98 (1 C, C(O), carmamate), 163.95 (1 C, C(O)OCH3), 170.98 (2 C, C(O)). HRMS 
(ESI): m/z: cacd for C32H59N4O10, [M+H]
+, 659.4226, found: 659.4218. 
 
Synthesis of benzamido-methoxycarbonylethyl-4,7-bis-(ethoxycarbonylmethyl)-
1,4,7-triaza cyclononane - tris-alkylated nonane 9: A solution of monoalkylated 
compound 6 (340 mg, 0.78 mmol) in trifluoroacetic acid in dichloromethane (60%, 25 
mL) was stirred overnight at room temperature. The solvent was evaporated at reduced 
pressure. The residue was re-dissolved in dichlorometane and the solvent was 
evaporated. This procedure was repeated several times to give a light yellow thick oil. 
1H NMR spectroscopy (CDCl3) revealed the disappearance of the signals assigned to 
the Boc group in the precursor compound. The oil (0.78 mmol, assuming quantitative 
deprotection) was dissolved in MeCN (30 mL), K2CO3 (1.0 g, 7.8 mmol) was added and 
the suspension was vigorously stirred at romm temperature for 15 minutes. Ethyl 
bromoacetate (0.21 mL, 1.88 mmol) was added and the suspension was further stirred at 
room temperature for 2.5 hours. The suspended solid was removed by filtration, the 
solvent was evaporated under reduced pressure and the residue was purified by flash 
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chromatography (100% CH2Cl2  CH2Cl2/EtOH (7:3)) to afford compound 9 (355 mg, 
37 %) as a white foam. 1H NMR (300 MHz, CDCl3): δ= 1.22 (m, 6 H, C(O)OCH2CH3),  
2.2-3.60 (broad multiplet, 18 H, N(CH2)2N, NCH2C(O) and NCH2CH), 3.71 (s, 3 H, 
C(O)OCH3), 4.11  (t, J= 7.5 Hz, C(O)OCH2CH3), 5.14 (m (br), 1 H, NCH2CH), 7.44-
8.03 (5H, m, Ar). 13C NMR (75.4 MHz, CDCl3): selected signals: 13.95 
(C(O)OCH2CH3), 48.74 (CH),  49.04 (CH2), 50.38 (CH2), 51.48 (CH2),  52.59 (CH2), 
52.95 (C(O)OCH3), 53.62 (NCH2CH), 53.62 (CH2), 54.86 (CH2), 54.96 (CH2), 55.19 
(CH2), 55.37 (CH2), 55.75 (CH2), 56.18 (CH2),  60.62 (CH2), 60.94, 61.13, 61.21 
(C(O)OCH2), 127.83 (Ar), 128.12 (Ar), 128.41 (Ar), 131.53 (Ar),  131.84 (Ar), 132.62 
(Ar), 167.79 (C(O), amide), 170.29 (2xC(O), ethyl ester), 170.52 (C(O), methyl ester), 
170.91 (C(O), ethyl ester?). HRMS (ESI): m/z: cacd for C25H39N4O7, [M+H]
+, 
507.2813, found: 507.2807. 
 
Synthesis of 1-(4-Pyrenebutanamido)-carboxyethyl-4,7-bis-(ethoxycarbonylme 
thyl)-1,4,7-triaza cyclononane - tris-alkylated nonane 10: A solution of 
monoalkylated nonane 7 (0.69 g, 1.16 mmol)) in trifluoroacetic acid in dichlorometane 
(60%, 25 mL) was stirred overnight at room temperature. The solvent was evaporated at 
reduced pressure. The residue was re-dissolved in dichlorometane and the solvent was 
evaporated. This procedure was repeated several times to give a light yellow thick oil. 
1H NMR spectroscopy (CDCl3) revealed the disappearance of the signals assigned to 
the Boc group in precursor 7. The oil (1.16 mmol, assuming quantitative deprotection) 
was dissolved in MeCN (30 mL), K2CO3 (1.6 g, 11.5 mmol) was added and the 
suspension was vigorously stirred at room temperature for 15 minutes. To this 
suspension was added ethyl bromoacetate (0.31 mL, 2.77 mmol). The suspension was 
vigorously stirred at room temperature overnight. The suspended solid was removed by 
filtration, the solvent was evaporated under reduce pressure and the residue was purified 
by flash chromatography (100% CH2Cl2  CH2Cl2/EtOH (1:1)) to afford compound 10 
(0.425 g, 55 %) as a white foam. 1H NMR (300 MHz, CDCl3): δ = 1.26 (m, 6 H, 
2xC(O)OCH2CH3), 2.24 (m, 2 H, NHC(O)CH2CH2), 2.44 (m, 2 H, NHC(O)CH2), 2.60-
2.90 (m, 4 H, NCH2C(O)), 2.50-3.40 (m, 16 H, N(CH2)2N, NCH2C(O), NCH2CH),  3.37 
(m, 2 H, NHC(O)(CH2)2CH2), 3.73 (s, 3 H, C(O)OMe), 3.92 (m, 4 H), 4.10 (m, 6 H, 
C(O)OCH2), 4.81(d(br), 1 H, NCH2CH), 7.80-8.40 (9 H, m, Ar). 
13C NMR (75.4 MHz, 
CDCl3): selected signals: 14.05 and 14.13 (C(O)OCH2CH3), 27.23 (C(O)CH2CH2), 
32.67 (NHC(O)(CH2)2CH2), 35.39 (C(O)CH2), 43.50 (CH2), 43.76 (CH2), 43.98 
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(CH2), 48.06 (CH2), 51.22 (CH2), 51.72(CH2), 51.86 (C(O)OCH3), 52.51 (CH), 52.60 
(CH2), 55.40 (CH2), 55.64 (CH2), 60.82, 60.98 (C(O)OCH2), 123.63 (Ar), 124,62 (Ar), 
124.75 (Ar), 124.85 (Ar), 125.76 (Ar), 126.51 (Ar), 127.18 (Ar), 127.41 (Ar), 127.46 
(Ar),  128.67 (Ar), 129.72 (Ar), 130.87 (Ar), 131.32 (2xAr), 136.43 (C), 136.53 (Ar), 
171.36 (C(O), ethyl ester), 171.39 (C(O), ethyl ester), 171.54 (C(O), methyl 
ester),173.64 (C(O), amide). 
  
Synthesis of fully deprotected ligands L1, L2 and L3 
   
Synthesis of aminocarboxyethyl-4,7-bis-(carboxymethyl)-1,4,7-triazacyclononane- 
fully deprotected NO2A-N-(-amino)propionic acid ligand (L1): A solution of 
prochelator 8 (50 mg, 0.076 mmol) in a mixture hydrochloric acid 6M/ethanol (12 mL; 
2/1 (v/v)) was stirred at room temperature for 2 hours. The solvent was evaporated 
under reduced pressure and the residue was re-dissolved in a mixture water/ethanol (10 
mL; 1/1 (v/v)). The solution was adjusted to pH ~10 with Dowex-1X2100-OH- resin (10 
mL, wet resin) and the suspension was stirred for 1 hour at room temperature. The resin 
was transferred into a column, washed with water and further eluted with hydrochloric 
acid 0.1 M. The relevant fractions, identified by TLC (ethanol water 1/1, revelation with 
iodine vapor) were pooled together and evaporated at reduced pressure to afford ligand 
L1 in the hydrochloride form as a off-white solid (25 mg, quantitative yield).1H NMR 
(300 MHz, D2O):= 2.73-3.67 (m, 16 H, N(CH2)2N and NCH2CO2H), 3.06 (d, J = 3.9 
Hz and x Hz, 1 H, ABX), 3.31 (dd, J= 12.3 and 3.9 Hz, 1 H, ABX), 5.01 (dd, J=10.5 
and 3.9 Hz 1 H, ABX). 13C NMR (75.4 MHz, D2O): 48.71 (CH2), 49.04 (CH2), 49.50 
(CH2), 50.93(CH2), 51.68 (CH2), 53.35 (CH), 57.31 (CH2), 57.93 (CH2), 58.46 (CH2), 
173.31 (CO2H), 174.99 (CO2H), 176.42 (CO2H). HRMS (ESI) m/z: cacd for 
C13H25N4O6 [M+H]
+: 333.1769, found: 333.1769. 
 
Synthesis of benzamido-carboxyethyl-4,7-bis-(carboxymethyl)-1,4,7-triazacyclono 
nane- fully deprotected NO2A-N-(-benzoylamido)propionic acid ligand (L2): 
Prochelator (9) (323 mg, 0.89 mmol) was dissolved in a mixture ethanol/water (20 mL, 
1/1 (v/v)). The solution was adjusted to pH ~10 by adding small portions of Dowex 
1X2-100-OH- resin. The suspension was stirred gently at room temperature for 2 hours. 
The wet resin was transferred into a chromatography column, washed with water (~50 
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mL) and eluted with hydrochloric acid 0.1 M. The relevant fractions, identified by TLC 
(ethanol water 1/1, revelation with iodine vapor) were pooled, concentrated at room 
temperature and further dried under vacuum to afford ligand L2, in the hydrochloride 
form, as a light yellow solid (180 mg, 71 %). 1H NMR (300 MHz, D2O): δ= 2.9-3.6 
(broad, overlapped signals with a integration corresponding to 14 H, N(CH2)2N and 
NCCH2CH), 3.81 (broad, overlapped signals with a integration corresponding to 4 H, 
NCH2CO2H), 4.80 (m (broad), 1 H, CH), 7.53-7.88 (5 H, m, Ar). 
13C NMR (75.4 MHz, 
D2O): selected signals: 43.02 (CH2), 48.11 (CH2), 48.93 (CH2), 49.03 (CH2), 49.78 
(CH2), 51.39 (CH2),  51.71 (CH), 51.91 (CH2), 54.53 (CH2), 56.08 (CH2), 56.77 (CH2), 
127.46 (Ar), 129.04 (Ar), 132.60 (Ar), 133.32 (Ar), 170.20 (CO2H), 177.17 (C(O), 
amide). HRMS (ESI): m/z: cacd for C20H29N4O7, [M+H]
+, 437.2031, found: 437.2027. 
 
Synthesis of 1-(4-Pyrenebutanamido)-carboxyethyl-4,7-bis-(carboxymethyl)-1,4,7-
triazacyclononane- fully deprotected NO2A-N-(-pyrenebutanamido)propionic 
acid ligand (L3): Prochelator (10) (0.360 g, 0.53 mmol) was dissolved in a mixture 
ethanol/water (1/1 v/v, 20 ml). The solution was adjusted to pH ~ 10 by adding small 
portions of   Dowex 1X2-100-OH- resin. The suspension was kept under stirring at 
room temperature for 2 hours. The wet resin was transferred into a chromatography 
column, washed with water (~50 mL) and eluted with 0.1 M hydrochloric acid, 
followed by a mixture hydrochloric acid 0.2 M/ethanol (1/1 v/v). The relevant fractions, 
identified by TLC (ethanol/water, 1/1 v/v, revelation with  iodine vapor and 
visualization under UV light 365 nm) were pooled, concentrated at room temperature 
and further dried under vacuum to afford deprotected chelator L3 in the hydrochloride 
form, as a light yellow solid (0.149 g, 46 %).  1H NMR (400 MHz, D2O/CD3OD): δ= 
1.9-3.3 ( broad, overlapped signals with a integration corresponding to 24 H, 
NHC(O)CH2CH2CH2, NCH2CO2H, NCH2CH and N(CH2)2N)), 4.49 (m (br), 1 H, CH), 
7.80-8.40 (9 H, m, Ar). 13C NMR (75.4 MHz, D2O/CD3OD): selected signals: 28.22 
(C(O)CH2CH2), 33.25 ((C(O)(CH2)2CH2), 36.23 ((C(O)CH2), 50.49 (CH2), 
54.95 (CH2), CH2..., CH??? 122.75 (Ar), 123.97 (Ar), 124.03 (CH-Ar), 124.58 (2x(CH-
Ar)), 125.71 (CH-Ar), 126.19 (CH-Ar), 126.93 (C-Ar), 126.99 (CH-Ar), 127.28 (CH-
Ar), 127.92 (CH-Ar), 129.24 (C-Ar), 130.20 (C-Ar), 130.70 (C-Ar), 135.44 (C-Ar), 
171.98 (CO2H), 172.19 (2xCO2H), 175.41 (NHC(O)). HRMS (ESI): m/z: cacd for 
C33H38N4NaO7, [M+Na]
+, 625.2638, found: 625.2621. 
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Preparation of Ga3+ chelates for 1H and 71Ga NMR.   
To an aqueous solution of ligand (pH = 3.0) was added dropwise an aqueous solution of 
the GaCl3 in a 1:1 mole ratio. The pH was kept bellow 3.8 by the addition of aqueous 
NaOH. The solution was stirred at room temperature over night and the solvent was 
removed at reduced pressure. Solutions for NMR measurements (20 mM, D2O) were 
obtained by dissolution of the solid complexes in D2O (0.75 mL). 
1H and 71Ga NMR 
spectra of the complexes were obtained at 298 K on a Bruker Avance-3 400 Plus 
spectrometer, operating at 400.02 and 121.98 MHz, respectively. The proton NMR 
spectra of the complexes were assigned by 2D COSY and NOESY techniques using a 
Varian VNMRS 600 NMR spectrometer. The 1H and 71Ga NMR pH study of the 
complexes was performed by adding small portions of NaOD or DCl to the complex 
solutions to obtain the desired pH. 
 
Fluorescence Measurements  
The absorption and the fluorescence emission spectra of the free ligand L3 and the GaL3 
complex were recorded, respectively, with a Jasco V-630 UV-Vis spectrophotometer and 
a HORIBA JobinYvon Fluoromax-4 spectrofluorimeter, equipped with a 
monochromator in both excitation and emission and a temperature controlled cuvette 
holder. Fluorescence spectra were corrected for the instrumental response of the system. 
The fluorescence quantum yields (F) were determined using the standard method.52,53 
Anthracene in ethanol (Φr = 0.27)54 was used as reference. 
 
Radiochemistry 
67Ga3+ complexes for in vivo and in vitro  experiments were prepared by adding 1 mCi 
of [67Ga]citrate (produced at IBA Molecular, Louvain-la-Neuve)  to a solution of 1 mg 
of the chelator in Hepes buffer (400 μL, 0.4 M, pH 4) and heated at 80 ºC for ca 1 hour. 
The radiochemical purity of the final products was determined by TLC. The percentage 
of bound metal was above 95% in all cases. 
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Calculation of log P  
The lipophilicity of GaL2 and GaL3 complexes was assessed by computing their logP 
values using the alops software (free software available at 
http://www.vclab.org/lab/alogps).55 
 
Stability in blood serum 
For the blood serum stability studies, 5 μCi of a standard solution of [67Ga]L2 were 
added to 5 mL of fresh human serum, previously equilibrated in 5% CO2 (95% air) 
environment at 37 °C. The mixture was kept in the same environment, and aliquots of 
100 L (in triplicate) were taken at appropriate periods of time (0 min, 30 min, and 1 
hour). The aliquots were treated with 200 μL of ethanol, cooled (4 °C), and centrifuged 
during for 15 min at 4000 rpm, at 4 °C, in order to precipitate the serum proteins. A 100 
μL aliquot of supernatant was collected for activity counting in a γ well-counter. The 
sediment was washed twice with 1 mL of EtOH and its activity was counted. The 
activity of the supernatant was compared to that of the sediment in order to determine 
the percentage of the chelate associated to the proteins. The activity of the supernatant 
at 1 hour was evaluated by TLC in order to check whether the chelate remained intact. 
 
Biodistribution studies 
All animal studies were performed by authorized researchers in strict adherence to the 
Portuguese law for animal protection. 
 
Groups of four animals (Wistar male rats weighting ca 200 g) were anaesthetized with 
Ketamine (50.0 mg/mL)/chloropromazine (2.5%) (10:3), injected in the tail vein with ca 
100 Ci of [67Ga]L3 and sacrificed 1 and 24 hours later. The major organs were 
removed, weighted and counted in a  well-counter. The biodistribution is stated as 
percentage of injected dose per gram of organ (%ID/g).  
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Supplementary Information 
A)
 
B) 
 
Figure S1. A) 1D proton and B) 2D COSY NMR spectrum of GaL1 at pH 3.0 (600 MHz, 20 
mM in D2O, 25 ºC). 
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A)
B) 
 
Figure S2. A) 1D proton and B) 2D COSY NMR spectrum of GaL1 at pH 4.0 (600 MHz, 20 
mM in D2O, 25 ºC). 
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Figure S3.UV-Vis spectra for the free ligand L3 and of the GaL3 complex (1.0x10-5 M). 
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Figure S4. Fluorescence spectra for ligand L3 in non-deoxygenated water over the 
concentration range 1x10-7 - 5x10-3 mol.dm-3 (exc=345 nm). 
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Table S1. Computed  LogP values for the GaL2 and GaL3 complexes after structure 
optimization with Mopac PM6 COSMO, water implicit solvent. 
 
 
 
 
 
 
Figure S5. Optimized structure of GaL3 (Mopac PM6 COSMO, water implicit solvent). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Calculated logP 
GaL2 0.69 
GaL3 3.31 
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Table S2. Biodistribution, stated as percentage of injected dose per gram of organ 
(%ID/g ±SD), of [67Ga]L3 in Wistar rats at 1 and 24 hours after i.v. injection. Results are 
the mean of 4 animals. 
 
 
Organ 
1h 
%ID 
24h 
%ID 
blood 0.10007 0.000406308 
liver 0.350711 0.019477613 
spleen 0.04807 0.010971577 
kidney 0.817741 0.033667745 
heart 0.028524 0.002091018 
brain + cerebellum 0.002673 0.000355646 
lung 0.101831 0.006952801 
s. intestine 0.064156 0.004023468 
l. intestine 0.04826 0.003821414 
bone 0.027221 0.000864891 
muscle 0.023675 0.000383012 
 
 
